Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311169 | 0.79 | JAK2 (0.41) | ALDH1A1CYP1A2HPGDHSD17B10JAK2 | |
| SCHEMBL212131 | 0.79 | TLR7 (0.44) | ALDH1A1HPGDNUDT1HSD17B10OPRM1 | |
| SCHEMBL9076301 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1HPGDHSD17B10JAK2PDPK1 | |
| SCHEMBL487627 | 0.79 | MAOA (0.42) | ALDH1A1HPGDHSD17B10JAK2PDPK1 | |
| SCHEMBL487415 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CYP1A2HPGDHSD17B10JAK2 | |
| SCHEMBL29694218 | 0.79 | TLR7 (0.44) | ALDH1A1HPGDNUDT1HSD17B10OPRM1 | |
| SCHEMBL5507881 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1HPGDHSD17B10JAK2PDPK1 | |
| SCHEMBL7072625 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1HPGDHSD17B10JAK2PDPK1 | |
| SCHEMBL28506044 | 0.79 | TSHR (0.43) | ALDH1A1CYP1A2HPGDNUDT1HSD17B10 | |
| SCHEMBL28312743 | 0.79 | TLR7 (0.44) | ALDH1A1HPGDNUDT1HSD17B10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2018-07-03 | — | — | US | disclosed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | disclosed |
| US-20070166384-A1 | Methods , composition and preparations for delivery of immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| EP-0329073-B1 | 2-Substituted carbonylimidazo[4,5-c]quinolines | SHIONOGI & CO (JP) | 1994-12-28 | — | — | EP | disclosed |
| EP-0310950-B1 | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes | RIKER LABORATORIES, INC. (US) | 1993-01-13 | — | — | EP | disclosed |
| US-4940714-A | 2-substituted carbonylimidazo[4,5-c]quinolines | SHIONOGI & CO., LTD. (JP) | 1990-07-10 | — | — | US | disclosed |
| EP-0145340-B1 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0329891-A2 | End-functionalized low molecular weight polymers of ethylene | PETROLITE CORPORATION (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329073-A2 | 2-Substituted carbonylimidazo[4,5-c]quinolines | SHIONOGI & CO., LTD. (JP) | 1989-08-23 | — | — | EP | disclosed |
| EP-0310950-A1 | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes | RIKER LABORATORIES, INC. (US) | 1989-04-12 | — | — | EP | disclosed |
| US-4698348-A | 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents | RIKER LABORATORIES, INC. (US) | 1987-10-06 | — | — | US | disclosed |
| US-4689338-A | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use | RIKER LABORATORIES, INC. (US) | 1987-08-25 | — | — | US | disclosed |
| EP-0145340-A2 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NRAS, BRAF, KRAS | GPR3 3384/4885ALDH1A1 2338/4885CYP1A2 1232/4885 |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NRAS, BRAF, KRAS | GPR3 3384/4885ALDH1A1 2338/4885CYP1A2 1232/4885 |
| US-20070166384-A1 | Methods , composition and preparations for delivery of immune response modifiers | TLR3, MYD88, IFNG | GPR3 1942/4885ALDH1A1 3571/4885CYP1A2 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.